Elranatamab-bcmm Approved for Adult Patients With Relapsed or Refractory Multiple Myeloma
The novel drug elranatamab-bcmm (Elrexfio) received accelerated FDA approval on August 14, 2023, for treating adults with relapsed or refractory multiple myeloma.
Relyvrio: A New FDA-Approved Treatment for Patients With ALS
Relyvrio is intended to slow the disease progression of amyotrophic lateral sclerosis.
FDA Approves Olipudase Alfa-rpcp for Acid Sphingomyelinase Deficiency
Acid sphingomyelinase deficiency is a rare, progressive genetic disease associated with significant morbidity and mortality.